Adiponectin knockout accentuates high fat diet-induced obesity and cardiac dysfunction: Role of autophagy

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 8, 2013, Pages 1136-1148

  Guo, Rui ^a   Zhang, Yingmei ^a,b   Turdi, Subat ^a   Ren, Jun ^a,b  

^a UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adiponectin; Autophagy; Cardiac function; Hypertrophy; Metabolism; Obesity

Indexed keywords

ADIPONECTIN; BECLIN 1; CALCIUM ION; FATTY ACID; FATTY ACID SYNTHASE; GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P62; RAPAMYCIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DEPHOSPHORYLATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOCARDIOGRAPHY; ENERGY EXPENDITURE; FATTY ACID METABOLISM; GLUCOSE TOLERANCE; HEART CONTRACTION; HEART DISEASE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; LIPID DIET; LIPID STORAGE; METABOLIC RATE; MOUSE; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL;

ABSORPTIOMETRY, PHOTON; ADIPONECTIN; ANIMALS; AUTOPHAGY; CALCIUM; CARDIOMEGALY; DIET, HIGH-FAT; ECHOCARDIOGRAPHY; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEART; LIPID METABOLISM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; OBESITY; PHOSPHORYLATION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 84877355166     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.03.013     Document Type: Article

References (65)

1. Poirier P., Giles T.D., Bray G.A., Hong Y., Stern J.S., Pi-Sunyer F.X., Eckel R.H. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition. Phys. Act. Metab. Circ. 2006, 113:898-918.
2. Zanella M.T., Kohlmann O., Ribeiro A.B. Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001, 38:705-708.
3. Steinberger J., Daniels S.R. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 2003, 107:1448-1453.
4. Heusch G. Obesity and inflammatory vasculopathy: a surgical solution as ultima ratio?. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1953-1954.
5. Relling D.P., Esberg L.B., Fang C.X., Johnson W.T., Murphy E.J., Carlson E.C., Saari J.T., Ren J. High-fat diet-induced juvenile obesity leads to cardiomyocyte dysfunction and upregulation of Foxo3a transcription factor independent of lipotoxicity and apoptosis. J. Hypertens. 2006, 24:549-561.
6. Sparks L.M., Xie H., Koza R.A., Mynatt R., Hulver M.W., Bray G.A., Smith S.R. A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes 2005, 54:1926-1933.
7. Dong F., Li Q., Sreejayan N., Nunn J.M., Ren J. Metallothionein prevents high-fat diet induced cardiac contractile dysfunction: role of peroxisome proliferator activated receptor gamma coactivator 1alpha and mitochondrial biogenesis. Diabetes 2007, 56:2201-2212.
8. Vasan R.S. Cardiac function and obesity. Heart 2003, 89:1127-1129.
9. de Divitiis O., Fazio S., Petitto M., Maddalena G., Contaldo F., Mancini M. Obesity and cardiac function. Circulation 1981, 64:477-482.
10. Li S.Y., Yang X., Ceylan-Isik A.F., Du M., Sreejayan N., Ren J. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 2006, 49:1434-1446.
11. Carr M.C., Brunzell J.D. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J. Clin. Endocrinol. Metab. 2004, 89:2601-2607.
12. Fasshauer M., Paschke R., Stumvoll M. Adiponectin, obesity, and cardiovascular disease. Biochimie 2004, 86:779-784.
13. Kawano J., Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J. Cardiometab. Syndr. 2009, 4:44-49.
14. Hopkins T.A., Ouchi N., Shibata R., Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc. Res. 2007, 74:11-18.
15. Goldstein B.J., Scalia R.G., Ma X.L. Protective vascular and myocardial effects of adiponectin. Nat. Clin. Pract. Cardiovasc. Med. 2009, 6:27-35.
16. Duda M.K., O'Shea K.M., Lei B., Barrows B.R., Azimzadeh A.M., McElfresh T.E., Hoit B.D., Kop W.J., Stanley W.C. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc. Res. 2007, 76:303-310.
17. Fujita K., Maeda N., Sonoda M., Ohashi K., Hibuse T., Nishizawa H., Nishida M., Hiuge A., Kurata A., Kihara S., Shimomura I., Funahashi T. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler. Thromb. Vasc. Biol. 2008, 28:863-870.
18. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., Funahashi T., Ouchi N., Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 2005, 11:1096-1103.
19. Shibata R., Ouchi N., Ito M., Kihara S., Shiojima I., Pimentel D.R., Kumada M., Sato K., Schiekofer S., Ohashi K., Funahashi T., Colucci W.S., Walsh K. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 2004, 10:1384-1389.
20. Lopaschuk G.D., Folmes C.D., Stanley W.C. Cardiac energy metabolism in obesity. Circ. Res. 2007, 101:335-347.
21. Liao Y., Takashima S., Maeda N., Ouchi N., Komamura K., Shimomura I., Hori M., Matsuzawa Y., Funahashi T., Kitakaze M. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res. 2005, 67:705-713.
22. Ingelsson E., Riserus U., Berne C., Frystyk J., Flyvbjerg A., Axelsson T., Lundmark P., Zethelius B. Adiponectin and risk of congestive heart failure. JAMA 2006, 295:1772-1774.
23. Aprahamian T.R., Sam F. Adiponectin in cardiovascular inflammation and obesity. Int. J. Inflamm. 2011, 2011:376909.
24. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257:79-83.
25. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., Iwahashi H., Kuriyama H., Ouchi N., Maeda K., Nishida M., Kihara S., Sakai N., Nakajima T., Hasegawa K., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Hanafusa T., Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1595-1599.
26. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., Arita Y., Okamoto Y., Shimomura I., Hiraoka H., Nakamura T., Funahashi T., Matsuzawa Y. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 2003, 23:85-89.
27. Iwashima Y., Katsuya T., Ishikawa K., Ouchi N., Ohishi M., Sugimoto K., Fu Y., Motone M., Yamamoto K., Matsuo A., Ohashi K., Kihara S., Funahashi T., Rakugi H., Matsuzawa Y., Ogihara T. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43:1318-1323.
28. Yoon M.J., Lee G.Y., Chung J.J., Ahn Y.H., Hong S.H., Kim J.B. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 2006, 55:2562-2570.
29. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8:1288-1295.
30. Xie M., Morales C.R., Lavandero S., Hill J.A. Tuning flux: autophagy as a target of heart disease therapy. Curr. Opin. Cardiol. 2011, 26:216-222.
31. Goldman S., Zhang Y., Jin S. Autophagy and adipogenesis: implications in obesity and type II diabetes. Autophagy 2010, 6:179-181.
32. Yang L., Li P., Fu S., Calay E.S., Hotamisligil G.S. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 2010, 11:467-478.
33. Yorimitsu T., Klionsky D.J. Autophagy: molecular machinery for self-eating. Cell Death Differ. 2005, 12(Suppl. 2):1542-1552.
34. Nemchenko A., Chiong M., Turer A., Lavandero S., Hill J.A. Autophagy as a therapeutic target in cardiovascular disease. J. Mol. Cell. Cardiol. 2011, 51:584-593.
35. Xie Z., Lau K., Eby B., Lozano P., He C., Pennington B., Li H., Rathi S., Dong Y., Tian R., Kem D., Zou M.H. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 2011, 60:1770-1778.
36. Liu H.Y., Han J., Cao S.Y., Hong T., Zhuo D., Shi J., Liu Z., Cao W. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J. Biol. Chem. 2009, 284:31484-31492.
37. Li Z.L., Woollard J.R., Ebrahimi B., Crane J.A., Jordan K.L., Lerman A., Wang S.M., Lerman L.O. Transition from obesity to metabolic syndrome is associated with altered myocardial autophagy and apoptosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1132-1141.
38. Xu X., Hua Y., Sreejayan N., Zhang Y., Ren J. Akt2 knockout preserves cardiac function in high-fat diet-induced obesity by rescuing cardiac autophagosome maturation. J. Mol. Cell Biol. 2013, 5:61-63.
39. Chang G.R., Wu Y.Y., Chiu Y.S., Chen W.Y., Liao J.W., Hsu H.M., Chao T.H., Hung S.W., Mao F.C. Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. Basic Clin. Pharmacol. Toxicol. 2009, 105:188-198.
40. Marin T.M., Keith K., Davies B., Conner D.A., Guha P., Kalaitzidis D., Wu X., Lauriol J., Wang B., Bauer M., Bronson R., Franchini K.G., Neel B.G., Kontaridis M.I. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest. 2011, 121:1026-1043.
41. Stoica L., Zhu P.J., Huang W., Zhou H., Kozma S.C., Costa-Mattioli M. Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3791-3796.
42. Wang Y., Zheng Y., Nishina P.M., Naggert J.K. A new mouse model of metabolic syndrome and associated complications. J. Endocrinol. 2009, 202:17-28.
43. Manning W.J., Wei J.Y., Katz S.E., Litwin S.E., Douglas P.S. In vivo assessment of LV mass in mice using high-frequency cardiac ultrasound: necropsy validation. Am. J. Physiol. 1994, 266:H1672-H1675.
44. Gardin J.M., Siri F.M., Kitsis R.N., Edwards J.G., Leinwand L.A. Echocardiographic assessment of left ventricular mass and systolic function in mice. Circ. Res. 1995, 76:907-914.
45. Yen K., Le T.T., Bansal A., Narasimhan S.D., Cheng J.X., Tissenbaum H.A. A comparative study of fat storage quantitation in nematode Caenorhabditis elegans using label and label-free methods. PLoS One 2010, 5.
46. Turdi S., Guo R., Huff A.F., Wolf E.M., Culver B., Ren J. Cardiomyocyte contractile dysfunction in the APPswe/PS1dE9 mouse model of Alzheimer's disease. PLoS One 2009, 4:e6033.
47. Peng Z., Borea P.A., Varani K., Wilder T., Yee H., Chiriboga L., Blackburn M.R., Azzena G., Resta G., Cronstein B.N. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J. Clin. Invest. 2009, 119:582-594.
48. Chang B.H., Li L., Paul A., Taniguchi S., Nannegari V., Heird W.C., Chan L. Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol. Cell. Biol. 2006, 26:1063-1076.
49. Yuan H., Perry C.N., Huang C., Iwai-Kanai E., Carreira R.S., Glembotski C.C., Gottlieb R.A. LPS-induced autophagy is mediated by oxidative signaling in cardiomyocytes and is associated with cytoprotection. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H470-H479.
50. Guo R., Scott G.I., Ren J. Involvement of AMPK in alcohol dehydrogenase accentuated myocardial dysfunction following acute ethanol challenge in mice. PLoS One 2010, 5:e11268.
51. Karbowska J., Kochan Z. Role of adiponectin in the regulation of carbohydrate and lipid metabolism. J. Physiol. Pharmacol. 2006, 57(Suppl. 6):103-113.
52. Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 2002, 13:84-89.
53. Fu Y., Luo N., Klein R.L., Garvey W.T. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J. Lipid Res. 2005, 46:1369-1379.
54. Chung S., Wong T., Nagasaki H., Civelli O. Acute homeostatic responses to increased fat consumption in MCH1R knockout mice. J. Mol. Neurosci. 2010, 42:459-463.
55. Wan M., Easton R.M., Gleason C.E., Monks B.R., Ueki K., Kahn C.R., Birnbaum M.J. Loss of Akt1 in mice increases energy expenditure and protects against diet-induced obesity. Mol. Cell. Biol. 2012, 32:96-106.
56. Shimano M., Ouchi N., Shibata R., Ohashi K., Pimentel D.R., Murohara T., Walsh K. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J. Mol. Cell. Cardiol. 2010, 49:210-220.
57. Habib S.L. Mechanism of activation of AMPK and upregulation of OGG1 by rapamycin in cancer cells. Oncotarget 2011, 2:958-959.
58. Kanamori H., Takemura G., Goto K., Maruyama R., Tsujimoto A., Ogino A., Takeyama T., Kawaguchi T., Watanabe T., Fujiwara T., Fujiwara H., Seishima M., Minatoguchi S. The role of autophagy emerging in postinfarction cardiac remodelling. Cardiovasc. Res. 2011, 91:330-339.
59. Groves B., Abrahamsen H., Clingan H., Frantz M., Mavor L., Bailey J., Ma D. An inhibitory role of the G-protein regulator AGS3 in mTOR-dependent macroautophagy. PLoS One 2010, 5:e8877.
60. Habeeb B.S., Kitayama J., Nagawa H. Adiponectin supports cell survival in glucose deprivation through enhancement of autophagic response in colorectal cancer cells. Cancer Sci. 2011, 102:999-1006.
61. Cowherd R.B., Asmar M.M., Alderman J.M., Alderman E.A., Garland A.L., Busby W.H., Bodnar W.M., Rusyn I., Medoff B.D., Tisch R., Mayer-Davis E., Swenberg J.A., Zeisel S.H., Combs T.P. Adiponectin lowers glucose production by increasing SOGA. Am. J. Pathol. 2010, 177:1936-1945.
62. Singh R., Kaushik S., Wang Y., Xiang Y., Novak I., Komatsu M., Tanaka K., Cuervo A.M., Czaja M.J. Autophagy regulates lipid metabolism. Nature 2009, 458:1131-1135.
63. Brown N.F., Stefanovic-Racic M., Sipula I.J., Perdomo G. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metabolism 2007, 56:1500-1507.
64. Russo S.B., Baicu C.F., Van Laer A., Geng T., Kasiganesan H., Zile M.R., Cowart L.A. Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J. Clin. Invest. 2012, 122:3919-3930.
65. Xu K., Yang Y., Yan M., Zhan J., Fu X., Zheng X. Autophagy plays a protective role in free cholesterol overload-induced death of smooth muscle cells. J. Lipid Res. 2010, 51:2581-2590.